CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

Jing Zhang; Izabela Sokal; Elaine R. Peskind; Joseph F. Quinn; Joseph Jankovic; Christopher Kenney; Kathryn A. Chung; Steven P. Millard; John G. Nutt; Thomas J. Montine

doi:10.1309/W01Y0B808EMEH12L

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

Jing Zhang, Izabela Sokal, Elaine R. Peskind, Joseph F. Quinn, Joseph Jankovic, Christopher Kenney, Kathryn A. Chung, Steven P. Millard, John G. Nutt, Thomas J. Montine

Neurology

Research output: Contribution to journal › Article › peer-review

249 Scopus citations

Abstract

The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and decreased amyloid (A) β₄₂ have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): τ, brain-derived neurotrophic factor, interleukin 8, Aβ₄₂, β₂-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

Original language	English (US)
Pages (from-to)	526-529
Number of pages	4
Journal	American journal of clinical pathology
Volume	129
Issue number	4
DOIs	https://doi.org/10.1309/W01Y0B808EMEH12L
State	Published - Apr 2008

Keywords

Alzheimer disease
Analyte profile
Biomarkers
Cerebrospinal fluid
Parkinson disease
Random forest algorithm

ASJC Scopus subject areas

Pathology and Forensic Medicine

Access to Document

10.1309/W01Y0B808EMEH12L

Cite this

@article{36dc9f22cf5441c28dec1334bf5f164b,

title = "CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases",

abstract = "The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and decreased amyloid (A) β42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): τ, brain-derived neurotrophic factor, interleukin 8, Aβ42, β2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.",

keywords = "Alzheimer disease, Analyte profile, Biomarkers, Cerebrospinal fluid, Parkinson disease, Random forest algorithm",

author = "Jing Zhang and Izabela Sokal and Peskind, {Elaine R.} and Quinn, {Joseph F.} and Joseph Jankovic and Christopher Kenney and Chung, {Kathryn A.} and Millard, {Steven P.} and Nutt, {John G.} and Montine, {Thomas J.}",

year = "2008",

month = apr,

doi = "10.1309/W01Y0B808EMEH12L",

language = "English (US)",

volume = "129",

pages = "526--529",

journal = "American journal of clinical pathology",

issn = "0002-9173",

publisher = "American Society of Clinical Pathologists",

number = "4",

}

TY - JOUR

T1 - CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

AU - Zhang, Jing

AU - Sokal, Izabela

AU - Peskind, Elaine R.

AU - Quinn, Joseph F.

AU - Jankovic, Joseph

AU - Kenney, Christopher

AU - Chung, Kathryn A.

AU - Millard, Steven P.

AU - Nutt, John G.

AU - Montine, Thomas J.

PY - 2008/4

Y1 - 2008/4

N2 - The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and decreased amyloid (A) β42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): τ, brain-derived neurotrophic factor, interleukin 8, Aβ42, β2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

AB - The therapeutic imperative for Alzheimer disease (AD) and Parkinson disease (PD) calls for discovery and validation of biomarkers. Increased cerebrospinal fluid (CSF) τ and decreased amyloid (A) β42 have been validated as biomarkers of AD. In contrast, there is no validated CSF biomarker for PD. We validated our proteomics-discovered multianalyte profile (MAP) in CSF from 95 control subjects, 48 patients with probable AD, and 40 patients with probable PD. An optimal 8-member MAP agreed with expert diagnosis for 90 control subjects (95%), 36 patients with probable AD (75%), and 38 patients with probable PD (95%). This MAP consisted of the following (in decreasing order of contribution): τ, brain-derived neurotrophic factor, interleukin 8, Aβ42, β2-microglobulin, vitamin D binding protein, apolipoprotein (apo) AII, and apoE. This first large-scale validation of a proteomic-discovered MAP suggests a panel of 8 CSF proteins that are highly effective at identifying PD and moderately effective at identifying AD.

KW - Alzheimer disease

KW - Analyte profile

KW - Biomarkers

KW - Cerebrospinal fluid

KW - Parkinson disease

KW - Random forest algorithm

UR - http://www.scopus.com/inward/record.url?scp=42949119345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949119345&partnerID=8YFLogxK

U2 - 10.1309/W01Y0B808EMEH12L

DO - 10.1309/W01Y0B808EMEH12L

M3 - Article

C2 - 18343778

AN - SCOPUS:42949119345

SN - 0002-9173

VL - 129

SP - 526

EP - 529

JO - American journal of clinical pathology

JF - American journal of clinical pathology

IS - 4

ER -

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this